{
  "id": 1642859,
  "title": "Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'",
  "url": "https://urgent.news/2026/08/16/big-pharmas-future-growth-rests-on-chinese-science-expert-says-we",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-16T18:00:16.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/big-pharmas-future-growth-rests-180016912.html"
  },
  "original_language": "en",
  "account": "China has overtaken the United States in clinical drug development and supply chain, according to a June Cure Innovation Index survey. Big Pharma has signed billion-dollar deals for Chinese-developed medicines, with a third of new drugs licensed coming from Chinese labs. Dr. Nathan Goodyear, an integrative medicine physician, warns that restricting these partnerships could lead to fewer drug candidates, longer timelines and less price competition. The U.S. Department of Health and Human Services has launched Operation TrailBlazer, warning of a critical window to act decisively on biotech investment. Congress introduced the Biotech Investment National Security Act to screen outbound biotech investment. Despite concerns, some American companies have chosen to keep their operations in the U.S. to maintain control over discovery, development and manufacturing. Experts agree that the U.S. lead in biotech is at risk, but building resilience rather than banning partnerships is the key to maintaining competitiveness.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}